Kosan's KOS-862, KOS-1584 data show some antitumor activity

By Elaine Rigoli

Tampa, Fla., June 5 - Kosan Biosciences Inc. said interim clinical data from a phase 1b dose-escalating clinical trial of KOS-862 administered in combination with trastuzumab (Herceptin) in patients with HER-2 metastatic breast cancer showed some antitumor activity.

Of 13 patients who received weekly doses of KOS-862 (at 75, 80 or 100 mg/m2) in combination with Herceptin after previously failing treatment with chemotherapy, antitumor activity was observed in three patients, including one confirmed and one unconfirmed partial response, and one patient with a greater than 90% reduction in a tumor marker.

A phase 2 clinical trial evaluating KOS-862 at 100 mg/m2 in combination with the standard recommended dose of Herceptin is ongoing, according to a news release.

Kosan also said its phase 1 clinical trial of KOS-1584 as a single agent, conducted in patients with advanced solid tumors, said indications of antitumor activity included a 13% tumor shrinkage in one patient with non-small cell lung cancer and a 40% decrease in tumor marker in a patient with advanced highly refractory ovarian cancer.

Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors, the release said.

Kosan is a biotechnology company located in Hayward, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.